Corrigendum to "Genipin-crosslinked albumin nanoparticles containing neratinib and silibinin: A dual-death therapy for triple negative breast cancer" [Int. J. Pharm. 648 (2023) 123570]

Int J Pharm. 2025 Jan 25:669:125132. doi: 10.1016/j.ijpharm.2024.125132. Epub 2024 Dec 31.

Authors

Rohan Ghadi¹, Pawan Kumar Pandey¹, Akash Gabhale¹, Aaradhya Wadikar¹, M Dharshini¹, Kaushik Kuche¹, Tushar Date¹, Sanyog Jain²

Affiliations

¹ Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Punjab 160062, India.
² Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Punjab 160062, India. Electronic address: [email protected].

PMID: 39743452
DOI: 10.1016/j.ijpharm.2024.125132

No abstract available

Publication types

Published Erratum